Previous pregnancy is a favourable prognostic factor in women with localised cutaneous melanoma

Acta Oncologica

Volumn 51, Issue 5, 2012, Pages 662-668

  Vihinen, Pia ^a   Vainio Kaila, Mari ^a   Talve, Lauri ^a   Koskivuo, Ilkka ^a   Syrjänen, Kari ^a   Pyrhönen, Seppo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; NULLIPARA; PREDICTOR VARIABLE; PREGNANCY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84862109739     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.673734     Document Type: Article

References (25)

1. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specifi c survival for women diagnosed with cancer during pregnancy or lactation: A registry-based cohort study. J Clin Oncol 2009;27:45-51.
2. Weisz B, Schiff E, Lishner M. Cancer in pregnancy: Maternal and fetal implications. Hum Reprod Update 2001;7:384-93.
3. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000;115:1000-7.
4. Reintgen DS, McCarty KS Jr, Vollmer R, Cox E, Seigler HF. Malignant melanoma and pregnancy. Cancer 1985;55: 1340-4.
5. Lens M, Rosdahl I, Ahlbom A, Farahmand BY, Synnerstad I, Boeryd B, et al. Effect of pregnancy on survival in woman with cutaneous malignant melanoma. J Clin Oncol 2004;22:4369-75.
6. Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: Current review on controversial issues. Cancer Causes Control 2008;19:437-42.
7. Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, Thomas F, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women's health initiative randomized trials. J Natl Cancer Inst 2011;103:1469-75.
8. ÓMeara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005;103:1217-26.
9. Stensheim H, Cvancarova M, Moller B, Fossa SD. Pregnancy after adolescent and adult cancer: A populationbased matched cohort study. Int J Cancer 2011;129: 1225-36.
10. Oduncu FS, Kimmig R, Hepp H, Emmerich B. Cancer in pregnancy: Maternal-fetal confl ict. J Cancer Res Clin Oncol 2003;129:133-46.
11. Alexander A, Samlowski W, Grossman D, Bruggers CS, Harris RM, Zone JJ, et al. Metastatic melanoma in pregnancy: Risk of transplacental metastases in the infant. J Clin Oncol 2003;21:2179-86.
12. Pages C, Robert C, Thomas L, Maubec E, Sassolas B, Granel-Brocard F, et al. Management and outcome of metastatic melanoma during pregnancy. Br J Dermatol 2010;162:274-81.
13. Brady MS, Noce NS. Pregnancy is not detrimental to the melanoma patient with localized disease. J Clin Aesthetic Dermatol 2010;3:22-8.
14. Daryanani D, Plukker JT, De Hullu JA, Kuiper H, Nap RE, Hoekstra HJ. Pregnancy and early stage melanoma. Cancer 2003;97:2248-53.
15. Hersey P, Morgan G, Stone DE, McCarthy WH, Milton GW. Previous pregnancy as a protective factor against death from melanoma. Lancet 1977;1:451-2.
16. Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M. Reproductive history and cutaneous malignant melanoma: A comparison between women and men. Am J Epidemiol 2007;165:1265-70.
17. Lea CS, Holly EA, Hartge B, Lee JS, Guerry D, Elder DE, et al. Reproductive risk factor for cutaneous melanoma in women: A case-control study. Am J Epidemiol 2007;165: 505-13.
18. Nading MA, Nanney LB, Boyd AS, Ellis DL. Estrogen receptor beta expression in nevi during pregnancy. Exp Dermatol 2008;17:489-97.
19. Zhao D, Dahlman-Wright K, Gustafsson JA. Estrogen receptor : An overview and update. Nucl Recept Signal 2008;6e003.
20. Schmidt AN, Nanney LB, Boyd AS, King LE Jr, Ellis DL. Oestrogen receptor- expression in melanocytic lesions. Exp Dermatol 2006;15:971-80.
21. de Giorgi V, Sestini S, Gori A, Mazzotta C, Grazzini M, Rossarini S, et al. Polymorphisms of estrogen receptors: Risk factors for invasive melanoma - a prospective study. Oncology 2011;80:232-7.
22. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the million women study: Cohort study. BMJ 2007;335:1134-45.
23. Menzies AM, Visintin L, Chatfi eld MD, Carlino MS, Howle JR, Scolyer RA, et al. BRAF mutation by age-decade and body mass index in metastatic melanoma. J Clin Oncol 2011;29(Suppl; abstr 8507).
24. Joosse A, de Vries E, Eckel R, Nijsten T, Eggermont AM, Hölzer D, et al. Gender differences in melanoma survival: Female patients have a decreased risk of metastasis. J Invest Dermatol 2011;131:719-26.
25. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classifi cation. J Clin Oncol 2009;27:6199-206.